Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MATN
Previous SymbolNASDAQ:MATN
CUSIPN/A
Phone650-635-7000
Debt
Debt-to-Equity RatioN/A
Current Ratio1.05
Quick Ratio1.32
Price-To-Earnings
Trailing P/E Ratio-0.26
Forward P/E Ratio-1.69
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)($0.52)
Net Income$-13,810,000.00
Net MarginsN/A
Return on Equity-4,138.38%
Return on Assets-397.10%
Miscellaneous
Employees2
Outstanding Shares41,420,000
Market Cap$5.60 million
OptionableNot Optionable
Mateon Therapeutics (OTCMKTS:MATN) Frequently Asked Questions
What is Mateon Therapeutics' stock symbol?
Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN."
How were Mateon Therapeutics' earnings last quarter?
Mateon Therapeutics Inc (OTCMKTS:MATN) posted its quarterly earnings results on Wednesday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02). View Mateon Therapeutics' Earnings History.
When is Mateon Therapeutics' next earnings date?
What price target have analysts set for MATN?
1 brokerages have issued twelve-month target prices for Mateon Therapeutics' shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Mateon Therapeutics' stock price to reach $1.00 in the next year. This suggests a possible upside of 640.2% from the stock's current price. View Analyst Price Targets for Mateon Therapeutics.
What is the consensus analysts' recommendation for Mateon Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mateon Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mateon Therapeutics.
Has Mateon Therapeutics been receiving favorable news coverage?
News headlines about MATN stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mateon Therapeutics earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Mateon Therapeutics' key competitors?
Some companies that are related to Mateon Therapeutics include CytRx (CYTR), Vaxart (VXRT), Genetic Technologies (GENE), Arsanis (ASNS), Mymetics (MYMX), TrovaGene (TROV), aTyr Pharma (LIFE), Windtree Therapeutics (WINT), Microbot Medical (MBOT), Enzon Pharmaceuticals (ENZN), Neuralstem (CUR), Titan Pharmaceuticals (TTNP), Vitro Diagnostics (VODG), Taxus Cardium Pharmaceuticals Group (CRXM) and Omni Bio Pharmaceutical (OMBP).
Who are Mateon Therapeutics' key executives?
Mateon Therapeutics' management team includes the folowing people:
- Dr. William D. Schwieterman, Chairman, CEO & Pres (Age 60)
- Mr. Matthew M. Loar, Chief Financial Officer (Age 55)
- Ms. Shari Annes, Exec. Officer of Investor Relations
- Dr. Yuval Binur, Exec. VP of Financial
- Ms. Pamela Ha, Controller
How do I buy shares of Mateon Therapeutics?
Shares of MATN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mateon Therapeutics' stock price today?
One share of MATN stock can currently be purchased for approximately $0.1351.
How big of a company is Mateon Therapeutics?
Mateon Therapeutics has a market capitalization of $5.60 million. The biopharmaceutical company earns $-13,810,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Mateon Therapeutics employs 2 workers across the globe.
What is Mateon Therapeutics' official website?
How can I contact Mateon Therapeutics?
Mateon Therapeutics' mailing address is 701 GATEWAY BLVD SUITE 210, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-635-7000 or via email at [email protected]
MarketBeat Community Rating for Mateon Therapeutics (OTCMKTS MATN)
MarketBeat's community ratings are surveys of what our community members think about Mateon Therapeutics and other stocks. Vote "Outperform" if you believe MATN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MATN will underperform the S&P 500 over the long term. You may vote once every thirty days.
